TVT 2019 – Chicago
June 12-15, 2019
Transcatheter valve therapy (TVT) has emerged as a growing new treatment option for patients with valvular heart disease. TVT is the featured core of the Structural Heart Disease Summit. The landscape of TVT is rapidly evolving with the maturation of Transcatheter Aortic Valve Replacement (TAVR) and rapid ascension of transcatheter mitral and tricuspid therapies.
A common theme has been the integration of non-invasive cardiac imaging, surgical experiences, heart failure expertise, and novel transcatheter approaches as part of a multidisciplinary heart team for the diagnosis and planning of optimal treatment in patients with complex valvular heart disease. Importantly, structural heart disease is a burgeoning new subspecialty fueled by many other clinically important transcatheter procedures, led by left atrial appendage (LAA) and patent foramen ovale (PFO) closures.
TVT, the Structural Heart Summit, now in its twelfth year, is designed for a multidisciplinary audience of clinical practitioners, healthcare professionals, academicians, engineers, and scientists – including clinical cardiologists, cardiac imaging specialists (especially echo and CT), cardiac and vascular surgeons, electrophysiologists, heart failure specialists, nurse practitioners and physician assistants, cath lab technicians, other healthcare professionals, and members of the medical device community who are interested in valvular and structural heart disease.
TVT will provide a comprehensive review of the best clinical practices in the management of valvular and structural heart disease (including LAA and PFO closure therapies), including in-depth coverage of less invasive transcatheter devices currently in clinical use or under investigation.